Literature DB >> 24867124

Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review.

Suhila Sawesi1, Janet S Carpenter2, Josette Jones3.   

Abstract

Despite improved breast cancer survival rates with the use of tamoxifen and aromatase inhibitors, patients remain at risk for cancer recurrence and mortality because of nonadherence to medication. The objective of this review was to identify factors associated with nonadherence among patients with breast cancer. Electronic databases were searched for studies, and potentially relevant studies were retrieved and assessed for eligibility. Potential factors associated with nonadherence were identified, and they included patient-related factors (e.g., patient beliefs and knowledge, fear of adverse effects, forgetfulness, smoking, age, race), therapy-related factors (e.g., duration, side effects, additional prescribed medications, treatment interfering with lifestyle), healthcare system factors (e.g., patient/provider relationships), socioeconomic factors (e.g., medication costs, burden, scheduling problems, religion, marital status), and disease-related factors (e.g., comorbidities, stage of breast cancer). Those findings highlight the need for development of interventions to promote long-term adherence in patients with breast cancer.

Entities:  

Keywords:  aromatase inhibitors; breast cancer; chemotherapy; informatics and electronic health records; patient/public education; tamoxifen

Mesh:

Substances:

Year:  2014        PMID: 24867124     DOI: 10.1188/14.CJON.E50-E57

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  17 in total

1.  Adherence to tamoxifen in breast cancer patients: What role does the pharmacist play in German primary care?

Authors:  Madlene Schulz; Lena Klopp-Schulze; Stefanie Keilhack; Sandra Meyer; Lea Botermann; Charlotte Kloft
Journal:  Can Pharm J (Ott)       Date:  2018-12-20

2.  African-American Cancer Survivors' Use of Religious Beliefs to Positively Influence the Utilization of Cancer Care.

Authors:  Jill B Hamilton; Kayoll V Galbraith; Nakia C Best; Valarie C Worthy; L T C Angelo D Moore
Journal:  J Relig Health       Date:  2015-10

3.  Mammographic Density as a Biosensor of Tamoxifen Effectiveness in Adjuvant Endocrine Treatment of Breast Cancer: Opportunities and Implications.

Authors:  Maeve Mullooly; Ruth M Pfeiffer; Sarah J Nyante; Brandy M Heckman-Stoddard; Marjorie Perloff; Ismail Jatoi; Louise A Brinton; Erin J Aiello Bowles; Robert N Hoover; Andrew Glass; Amy Berrington de Gonzalez; Mark E Sherman; Gretchen L Gierach
Journal:  J Clin Oncol       Date:  2016-03-28       Impact factor: 44.544

Review 4.  Neuropsychiatric effects of tamoxifen: Challenges and opportunities.

Authors:  Andrew M Novick; Anthony T Scott; C Neill Epperson; Christopher D Schneck
Journal:  Front Neuroendocrinol       Date:  2020-08-18       Impact factor: 8.606

Review 5.  Dyadic Interventions for Cancer Survivors and Caregivers: State of the Science and New Directions.

Authors:  Hoda Badr; Jafar Bakhshaie; Karishma Chhabria
Journal:  Semin Oncol Nurs       Date:  2019-06-24       Impact factor: 2.315

6.  Adherence and quality of life in women with breast cancer being treated with oral hormone therapy.

Authors:  Rebeca Stahlschmidt; Amanda Canato Ferracini; Cinthia Madeira de Souza; Luana Moreira de Medeiros; Cassia Raquel Teatin Juliato; Priscila Gava Mazzola
Journal:  Support Care Cancer       Date:  2019-02-06       Impact factor: 3.603

7.  Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.

Authors:  Gretchen L Gierach; Rochelle E Curtis; Ruth M Pfeiffer; Maeve Mullooly; Estelle A Ntowe; Robert N Hoover; Sarah J Nyante; Heather Spencer Feigelson; Andrew G Glass; Amy Berrington de Gonzalez
Journal:  JAMA Oncol       Date:  2016-10-06       Impact factor: 31.777

8.  Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.

Authors:  Moriah J Brier; Dianne L Chambless; Robert Gross; Jinbo Chen; Jun J Mao
Journal:  Cancer       Date:  2016-08-29       Impact factor: 6.860

9.  Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study.

Authors:  Zerko Wako; Daniel Mengistu; Negalign Getahun Dinegde; Tseganesh Asefa; Mulugeta Wassie
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-06-09

10.  Both "Vitamin L for Life" and "One Milligram of Satan": A Multi-Perspective Qualitative Exploration of Adjuvant Endocrine Therapy Use after Breast Cancer.

Authors:  Kirsti I Toivonen; Devesh Oberoi; Kathryn King-Shier; Katherine-Ann L Piedalue; Joshua A Rash; Linda E Carlson; Tavis S Campbell
Journal:  Curr Oncol       Date:  2021-07-05       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.